Hot flashes that come out of nowhere. 3 a.m. wakeups that shred your next day. Mood swings, brain fog, and intimacy that no longer feels comfortable. If you are in your 40s or 50s and recognizing yourself here, you are not alone. Hormonal change is a normal transition, but the symptoms can be disruptive.
This clinician-reviewed guide walks you through what is typical in perimenopause and menopause, which bioidentical hormone replacement therapy (BHRT) options have the strongest safety data, how long therapy can continue, and what to expect if you taper or stop. You will also learn how we monitor treatment for safety and outcomes, and when non-hormonal options make sense.
Care is available in person at our Summerville and Nexton clinic, with telehealth across the Lowcountry for convenience and privacy.
Perimenopause is the transition leading up to menopause. Ovarian hormone output begins to fluctuate, especially progesterone early on, resulting in irregular cycles, heavier or lighter bleeding, breast tenderness, mood variability, and rising vasomotor symptoms such as hot flashes and night sweats. Sleep disruption and anxiety can intensify because of erratic progesterone and estradiol.
Menopause is a retrospective diagnosis. It begins after 12 consecutive months without a menstrual period. Estradiol production is persistently low, and many symptoms continue, including vasomotor symptoms, vaginal dryness, low libido, and joint stiffness. Bone density and cardiometabolic risk also evolve in this phase.
Why this distinction matters: treatment choices, doses, and monitoring differ. For example, a cycling perimenopausal patient may benefit from cyclic progesterone support with or without estradiol in later perimenopause, while a menopausal patient typically receives continuous estradiol with endometrial protection when needed.
Symptom scores at baseline and follow-up help assess response and guide dose adjustments.
When BHRT is appropriate, we align treatment with current guideline-backed options. The goal is the lowest effective dose that controls symptoms and supports function.
We also consider non-estrogen options when needed, including vaginal DHEA for GSM and non-hormonal therapies for hot flashes in select cases.
Duration is individualized. Current evidence supports using systemic hormone therapy for bothersome vasomotor symptoms and GSM, typically initiating before age 60 or within 10 years of menopause for the most favorable benefit-risk profile. There is no single mandatory stop date. Many women use BHRT for several years to control symptoms, then reassess.
Our approach:
Local vaginal estrogen for GSM can be continued long term because systemic exposure is minimal.
We combine symptom tracking with targeted labs and clinical follow-up. Typical elements include baseline labs, blood pressure and cardiovascular risk assessment, breast health screening per age and history, endometrial safety considerations when the uterus is present, and follow-up labs as indicated by the regimen. If pellets are used, we plan timing for re-dosing based on symptom return and lab targets, recognizing reduced flexibility once a pellet is placed.
If you stop systemic estrogen, vasomotor symptoms can return. Roughly half of women who discontinue experience some return of hot flashes or night sweats. Sleep and mood changes may also recur. Tapering gradually may reduce the abruptness of symptom return, but does not guarantee an easier transition. GSM typically persists or progresses without local treatment, so many patients continue vaginal estrogen even after stopping systemic therapy. Before stopping, we discuss a taper plan, alternatives, and support for sleep, mood, and bone health.
Caution is rooted in earlier interpretations of large trials that raised safety questions with specific oral, non-bioidentical regimens and older patient populations. More recent analyses differentiate timing, dose, route, and formulation. Today, many clinicians support HRT when started near menopause, especially with transdermal estradiol and micronized progesterone, and with ongoing monitoring. If you encounter a blanket no, it often reflects institutional policy or limited familiarity rather than your personal risk profile. A nuanced risk-benefit discussion is key.
Yes. Options include behavioral and lifestyle strategies for sleep and hot flashes, cognitive behavioral therapy for insomnia, non-hormonal medications such as certain SSRIs or SNRIs, gabapentin, or clonidine for vasomotor symptoms, and vaginal moisturizers and lubricants for GSM. Strength training, protein-forward nutrition, and alcohol moderation support body composition, mood, and sleep. These can be used alone or alongside local vaginal therapies.
For women concerned with weight gain during the transition, medically supervised programs can help address insulin resistance and appetite shifts common in midlife. If that is a priority, learn more about our structured, clinician-led support through our Charleston weight loss program.
If you are in the Lowcountry and exploring bioidentical hormones in Charleston or want guidance for summerville perimenopause BHRT, our Summerville and Nexton team can help you decide what is right for your body and goals.
If hot flashes, sleep loss, or GSM are affecting your daily life, you do not have to wait it out. Schedule a clinician-led review at our Summerville and Nexton clinic or meet via telehealth. We will outline options, discuss safety, and build a plan that fits your goals. Start with a conversation and decide together whether BHRT, local therapies, or non-hormonal care is the right next step.